Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Inhaled nitric oxide in ARDS.

James R Klinger1

  • 1Division of Pulmonary, Sleep and Critical Care Medicine, Brown University School of Medicine, Rhode Island Hospital, Providence, Rhode Island, USA. James_Klinger@brown.edu

Critical Care Clinics
|March 26, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of drug candidates for rescue of SOX17 gene targets in pulmonary arterial hypertension.

bioRxiv : the preprint server for biology·2026
Same author

Impaired SOX17 Expression Causes Endothelial Dysfunction and Pulmonary Arterial Hypertension by Insufficient Suppression of RUNX1.

bioRxiv : the preprint server for biology·2026
Same author

Evolving Concepts in Pulmonary Hypertension: Implementation Challenges of the Current Guidelines and Proceedings in the US.

Chest·2026
Same author

Exploring the Lung-Liver Axis in Pulmonary Arterial Hypertension.

Comprehensive Physiology·2026
Same author

Individualized Interactomes from Pulmonary Arterial Hypertension Cell Biopsies Predict Therapeutic Response.

medRxiv : the preprint server for health sciences·2025
Same author

The Liver is an Inflammatory Mediator of Pulmonary Arterial Hypertension.

bioRxiv : the preprint server for biology·2025

Inhaled nitric oxide (iNO) rapidly improves breathing in acute respiratory distress syndrome (ARDS). However, recent trials show no survival benefit, though combined therapies may help select patients.

Area of Science:

  • Physiology
  • Pulmonology
  • Critical Care Medicine

Background:

  • Nitric oxide (NO) plays a recently discovered role in physiological systems.
  • Inhaled NO (iNO) as a gas offers unique properties for immediate pulmonary hemodynamic and oxygenation improvements.
  • Numerous studies show acute physiological benefits of iNO in acute respiratory distress syndrome (ARDS).

Purpose of the Study:

  • To review the acute benefits of inhaled nitric oxide (iNO) in acute respiratory distress syndrome (ARDS).
  • To discuss the outcomes of recent randomized controlled trials (RCTs) of iNO in ARDS.
  • To explore potential future applications of iNO in ARDS management.

Main Methods:

  • Review of existing literature on inhaled nitric oxide (iNO) in ARDS.

Related Experiment Videos

  • Analysis of data from randomized controlled trials (RCTs) investigating iNO efficacy.
  • Exploration of adjunctive therapies and ventilator modalities used with iNO.

    • Main Results:

    • Acute improvements in pulmonary hemodynamics and oxygenation with iNO are well-documented.
    • Recent RCTs have not demonstrated improved outcomes (e.g., mortality) with iNO in ARDS.
    • The potential for iNO to benefit select patient groups remains under investigation.

    Conclusions:

    • While iNO shows acute physiological benefits in ARDS, its impact on patient outcomes requires further research.
    • Combining iNO with other treatments or ventilator strategies may offer future therapeutic potential.
    • Identifying specific patient populations who may benefit from iNO therapy is a key area for future studies.